Search results
Dow Jones Futures: Nasdaq Hits High, Eli Lilly Breaks Out, But Here Comes Nvidia
Investor's Business Daily· 36 minutes agoThe tech titan's earnings and guidance will have a huge impact on AI stocks and could have a major...
Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulins
CNBC· 10 hours agoA patient injects herself with an insulin pen. The rivalry between Eli Lilly and Novo Nordisk...
Eli Lilly Secures China Nod For Popular Weight Loss/Diabetes Drug Tirzepatide Why Is Eli Lilly Stock...
Benzinga· 14 hours agoOn Tuesday, Eli Lilly And Company LLY announced that Chinese regulators have approved its diabetes...
IBD Stock Of The Day Eli Lilly Breaks Out On Its Way To A Record High
Investor's Business Daily· 7 hours agoEli Lilly is Tuesday's IBD Stock Of The Day after shares surged into a buy zone, again, on promising...
Eli Lilly pays Aktis $60M upfront to further dial into radiopharma signal
FierceBiotech· 15 hours agoEli Lilly is continuing to ride the radiopharma wave, paying Aktis Oncology $60 million upfront to...
If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today | The...
The Motley Fool· 13 hours agoEli Lilly's (NYSE: LLY) broad portfolio of drugs has helped the company's earnings climb over the...
This overlooked obesity-drug stock has 80% upside, JPMorgan says
Business Insider via Yahoo Finance· 1 hour agoThe burgeoning GLP-1 weight loss market is expected to be worth $100 billion by 2030, leaving plenty...
Eli Lilly’s (LLY) diabetes injection Mufenda gets approval in China | Invezz
Invezz· 19 hours agoEli Lilly and Company announced on Tuesday that the National Medical Products Administration (NMPA)...
Eli Lilly’s stock on pace for record close as Crohn’s disease trial hits the mark
Market Watch· 11 hours agoEli Lilly & Co. LLY shares were on pace for a record closing high Tuesday after the drugmaker...
Unveiling Eli Lilly and Co (LLY)'s Value: Is It Really Priced Ri
Guru Focus· 8 hours agoAmidst a daily gain of 2.96% and a three-month gain of 8.32%, Eli Lilly and Co (LLY, Financial) presents a fascinating case for valuation analysis. This ...